Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y, Lok SW, Gibbs P, De Boer R, Yeo B, Greenberg S, Barnett F, Knott L, Richardson G, Wong R, Nottage M, Collins IM, Torres J, Lombard J, Johns J, Harold M, Malik L. Kanjanapan Y, et al. Among authors: collins im. Breast Cancer Res Treat. 2020 Nov;184(1):87-95. doi: 10.1007/s10549-020-05825-w. Epub 2020 Aug 10. Breast Cancer Res Treat. 2020. PMID: 32779037
Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study.
Tung I, Moldovan C, Wong V, De Boer R, Yeo B, Malik L, Greenberg S, Anton A, Nott L, Barnett F, Collins IM, Lombard J, Nottage M, Sahu A, Torres J, Gibbs P, Lok SW. Tung I, et al. Among authors: collins im. Clin Breast Cancer. 2022 Oct;22(7):e764-e772. doi: 10.1016/j.clbc.2022.07.005. Epub 2022 Jul 14. Clin Breast Cancer. 2022. PMID: 35941066
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.
Loft M, Lok SW, De Boer R, Malik L, Greenberg S, Yeo B, Anton A, Nottage M, Wong V, Nott L, Collins IM, Torres J, Barnett F, Lombard JM, Gibbs P, Gately L. Loft M, et al. Among authors: collins im. Breast Cancer Res Treat. 2023 Feb;198(1):67-74. doi: 10.1007/s10549-022-06856-1. Epub 2023 Jan 9. Breast Cancer Res Treat. 2023. PMID: 36624321
Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study.
Guccione L, Fisher K, Mileshkin L, Tothill R, Bowtell D, Quinn S, DeFazio A, Karapetis CS, Wilcken N, Singh M, Steer C, Gao B, Warren M, Collins IM, Karanth N, Bryant C, Schofield P. Guccione L, et al. Among authors: collins im. Support Care Cancer. 2022 Oct;30(10):8217-8229. doi: 10.1007/s00520-022-07228-7. Epub 2022 Jul 9. Support Care Cancer. 2022. PMID: 35804177 Free PMC article.
Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
Murphy C, Muscat A, Ashley D, Mukaro V, West L, Liao Y, Chisanga D, Shi W, Collins I, Baron-Hay S, Patil S, Lindeman G, Khasraw M. Murphy C, et al. PLoS One. 2019 Feb 14;14(2):e0210891. doi: 10.1371/journal.pone.0210891. eCollection 2019. PLoS One. 2019. PMID: 30763338 Free PMC article. Clinical Trial.
51 results